Regeneron Pharmaceuticals, Inc. (REGN) Misses Q1 EPS by 36c
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $900.16 +0.37%
EPS Growth %: +0.3%
Financial Fact:
Net loss before income tax benefit: 365.88M
Today's EPS Names:
BVFL, MCET, REOS, More
EPS Growth %: +0.3%
Financial Fact:
Net loss before income tax benefit: 365.88M
Today's EPS Names:
BVFL, MCET, REOS, More
Join SI Premium – FREE
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q1 EPS of $0.58, $0.36 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $626 million versus the consensus estimate of $609.04 million.
For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Chicopee Bancorp (CBNK) Tops Q1 EPS by 1c
- KBR, Inc. (KBR) PT Raised to $83 at Stifel
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
